{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:52:48Z","timestamp":1764996768375},"reference-count":448,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2005,7,8]],"date-time":"2005-07-08T00:00:00Z","timestamp":1120780800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1111\/j.1468-1293.2005.0311b.x","type":"journal-article","created":{"date-parts":[[2005,7,8]],"date-time":"2005-07-08T08:20:29Z","timestamp":1120810829000},"page":"1-61","source":"Crossref","is-referenced-by-count":84,"title":["British HIV Association (BHIVA) guidelines for the treatment of HIV\u2010infected adults with antiretroviral therapy (2005)"],"prefix":"10.1111","volume":"6","author":[{"given":"B","family":"Gazzard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the BHIVA Writing Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,8]]},"reference":[{"key":"e_1_2_18_2_2","unstructured":"Spartac Trial.http:\/\/www.aidsmap.com(accessed on 22 April 2005)."},{"key":"e_1_2_18_3_2","first-page":"79","article-title":"Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV\u2010infected patients","volume":"6","author":"Richter A","year":"2005","journal-title":"a retrospective cohort study"},{"key":"e_1_2_18_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.2.595-602.2001"},{"key":"e_1_2_18_5_2","first-page":"85","article-title":"Transmission of HIV\u20101 during primary infection","volume":"19","author":"Pao D","year":"2005","journal-title":"relationship to sexual risk and sexually transmitted infections"},{"key":"e_1_2_18_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.181"},{"key":"e_1_2_18_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013552"},{"key":"e_1_2_18_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200401230-00012"},{"key":"e_1_2_18_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000162337.58557.3d"},{"key":"e_1_2_18_10_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350400900106","article-title":"Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV","volume":"9","author":"Corzillius M","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_18_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_2_18_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_2_18_13_2","unstructured":"HicksCet al. RESIST\u20101: a phase 3 randomized controlled open\u2010label multicenter trial comparing tipranavir\/ritonavir (TPV\/r) to an optimized comparator protease inhibitor\/r (CPI\/r) regimen in antiretroviral (ARV) experienced patients: 24\u2010week data.44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC October 31\u2013November 2 2004 [Abstract H\u20101137a]."},{"key":"e_1_2_18_14_2","unstructured":"CahnPet al. 24\u2010week data from RESIST\u20102: phase 3 study of the efficacy and safety of either tipranavir\/ritonavir (TPV\/r) or an optimized ritonavir (RTV)\u2010boosted standard\u2010of\u2010care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment\u2010experienced HIV+patients.7th International Congress on Drug Therapy in HIV Infection. Glasgow Scotland 2004 [Abstract PL14.3]."},{"key":"e_1_2_18_15_2","first-page":"S174","article-title":"Pre\u2010existing L74V is a risk factor for virological non\u2010response and development of K65R in patients taking tenofovir DF (TDF)","volume":"9","author":"Bae A","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_18_16_2","unstructured":"MellorsJ PalmerS NissleyDet al. Low\u2010frequency NNRTI\u2010resistant variants contribute to failure of efavirenz\u2010containing regimens.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 39]."},{"key":"e_1_2_18_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.644-647.2004"},{"key":"e_1_2_18_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131391.91468.ff"},{"key":"e_1_2_18_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131377.28694.04"},{"key":"e_1_2_18_20_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/135965350400900301","article-title":"Persistence of multidrug\u2010resistant HIV\u20101 without antiretroviral treatment 2 years after sexual transmission","volume":"9","author":"Delaugerre C","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_18_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/379773"},{"key":"e_1_2_18_22_2","unstructured":"LittleSJ KoelschKK IgnacioCCet al. Persistence of transmitted drug\u2010resistant virus among subjects with primary HIV infection deferring antiretroviral therapy.11th CROI. San Francisco 2004 [Abstract 36LBPao 2004]."},{"key":"e_1_2_18_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200412150-00006"},{"key":"e_1_2_18_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.6.2713-2715.2003"},{"key":"e_1_2_18_25_2","first-page":"28","article-title":"Essential benefits of nucleoside analogue regimens in failing therapy","volume":"9","author":"Geretti AM.","year":"2004","journal-title":"J HIV Ther"},{"volume-title":"Clinical Effectivenss and Evaluation Unit. HIV Testing for Patients Attending General Medical Services \u2013 National Guidelines","year":"2005","author":"Royal College of Physicians.","key":"e_1_2_18_26_2"},{"key":"e_1_2_18_27_2","unstructured":"Medical Foundation for AIDS and Sexual Health.Recommended Standards for NHS HIV Services. Medical Foundation for AIDS and Sexual Health London 2003.http:\/\/www.medfash.org.uk(accessed on 17 May 2005)."},{"key":"e_1_2_18_28_2","unstructured":"MadgeS MatthewsP SinghS TheobaldN.HIV in Primary Care. Medical Foundation for AIDS and Sexual Health London 2004.http:\/\/www.medfash.org.uk(accessed on 17 May 2005)."},{"key":"e_1_2_18_29_2","unstructured":"Association of British Insurers.Statement of Best Practice on HIV Insurance. Association of British Insurers. London 2004.http:\/\/www.abi.org.uk(accessed on 16 May 2005)."},{"issue":"1","key":"e_1_2_18_30_2","first-page":"1","article-title":"British HIV Association (BHIVA) guidelines for the treatment on HIV\u2010infected adults with antiretroviral therapy","volume":"4","author":"Pozniak A","year":"2003","journal-title":"HIV Med"},{"key":"e_1_2_18_31_2","unstructured":"KatlamaC BergerD BellosNet al. Efficacy of TMC114\/r in 3\u2010class experienced patients with limited treatment options: 24\u2010week planned interim analysis of two 96\u2010week multinational dose\u2010finding trials.12th Conference on Retroviruses and Opportunistic Infections. Boston 2005 [Abstract Oral 164LB]."},{"key":"e_1_2_18_32_2","unstructured":"GazzardB PozniakA ArastehKet al. TMC 125 a next\u2010generation NNRTI demonstrates high potency after 7 days therapy in treatment\u2010experienced HIV\u20101\u2010infected individuals with phenotypic NNRTI resistance.9th Conference on Retroviruses and Opportunistic Infections. Seattle 2002 [Abstract 4]."},{"key":"e_1_2_18_33_2","unstructured":"The SMART Study.http:\/\/www.smart\u2010trial.org\/about.htm(accessed on 25 April 2005)."},{"key":"e_1_2_18_34_2","unstructured":"Health Protection Agency (HIV\/STI Department Communicable Disease Surveillance Centre). AIDS\/HIV Quarterly Surveillance Tables Cumulative UK Data To End September 2004 No. 64: 04\/3 October 2004."},{"key":"e_1_2_18_35_2","doi-asserted-by":"crossref","unstructured":"GreenG SmithR.The psychosocial and health care needs of HIV\u2010positive in the United Kingdom: a review HIV Medicine.2004;5(Suppl. 1):5\u201346.","DOI":"10.1111\/j.1468-1293.2004.00210.x"},{"key":"e_1_2_18_36_2","first-page":"233","article-title":"Effect of race and\/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection","volume":"117","author":"Palacio H","year":"2002","journal-title":"a review of the literature"},{"key":"e_1_2_18_37_2","unstructured":"Department of Health African HIV Policy Network National AIDS Trust HIV and AIDS in African communities: a framework for better prevention and care. 2004."},{"key":"e_1_2_18_38_2","unstructured":"Guidelines for the Management of HIV infection in Pregnant Women and the Prevention of Mother\u2010to\u2010Child Transmission of HIV. Drafthttp:\/\/www.bhiva.org.ukJanuary 2005."},{"key":"e_1_2_18_39_2","first-page":"2145","article-title":"Late presenters in the era of highly active antiretroviral therapy","volume":"18","author":"Sabin CA","year":"2004","journal-title":"uptake of and responses to antiretroviral therapy"},{"key":"e_1_2_18_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00267.x"},{"key":"e_1_2_18_41_2","unstructured":"Health Protection Agency's Centre for Infection. CD4 Surveillance Scheme. Colindale London. http:\/\/www.hpa.org.uk\/infections\/topics_02\/hiv_and_sti\/hiv\/epidemiology\/files\/hars_slideset.zip (accessed 7 June 2005)."},{"key":"e_1_2_18_42_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00126334-200008150-00013","article-title":"Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care?","volume":"24","author":"Mocroft A","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_18_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200304010-00009"},{"key":"e_1_2_18_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200304150-00006"},{"key":"e_1_2_18_45_2","unstructured":"EasterbrookPJ PhillipsAN HillTet al. U K The CHIC Study Patterns and predictors of antiretroviral drug use at treatment initiation in the UK.The XV International AIDS Conference. 2004 [Abstract TuPeB4543]."},{"key":"e_1_2_18_46_2","first-page":"27","article-title":"Reference ranges and sources of variability of CD4 counts in HIV\u2010seronegative women and men","volume":"72","author":"Maini MK","year":"1996","journal-title":"Genitourin Med"},{"key":"e_1_2_18_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309010-00012"},{"key":"e_1_2_18_48_2","first-page":"1071","article-title":"Gender differences in CD4+cell counts persist after HIV\u20101 infection","volume":"11","author":"Delmas AC","year":"1997","journal-title":"AIDS"},{"key":"e_1_2_18_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912030-00007"},{"key":"e_1_2_18_50_2","unstructured":"PrinsM MeyerL.Considering the dynamics of HIV infection by sex should treatment guidelines be revisited? The XV International AIDS Conference Bangkok 2004. AbstractTuPeB4539."},{"key":"e_1_2_18_51_2","first-page":"11","article-title":"Gender difference in HIV RNA levels","volume":"31","author":"Napravnik S","year":"2002","journal-title":"a meta-analysis of published studies"},{"key":"e_1_2_18_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/376638"},{"key":"e_1_2_18_53_2","first-page":"197","article-title":"Gender and clinical outcomes after starting highly active antiretroviral treatment","volume":"29","author":"Moore AL","year":"2002","journal-title":"a cohort study"},{"key":"e_1_2_18_54_2","first-page":"452","article-title":"Virologic, immunologic, and clinical response to highly active antiretroviral therapy","volume":"32","author":"Moore AL","year":"2003","journal-title":"the gender issue revisited"},{"key":"e_1_2_18_55_2","unstructured":"PattersonK NapravnikS EronJet al. Age and sex effect on response to initial HAART.Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 596]."},{"key":"e_1_2_18_56_2","first-page":"159","article-title":"Gender differences in virologic response to treatment in an HIV\u2010positive population","volume":"26","author":"Moore AL","year":"2001","journal-title":"a cohort study"},{"key":"e_1_2_18_57_2","doi-asserted-by":"publisher","DOI":"10.1086\/425075"},{"key":"e_1_2_18_58_2","unstructured":"AnastosK SchneiderM.Effect of race on the response to highly\u2010active antiretroviral therapy.Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 560]."},{"key":"e_1_2_18_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205240-00007"},{"key":"e_1_2_18_60_2","first-page":"2237","article-title":"Migrants from Sub\u2010Saharan Africa in the Swiss HIV Cohort Study","volume":"17","author":"Staehelin C","year":"2003","journal-title":"access to antiretroviral therapy, disease progression and survival"},{"key":"e_1_2_18_61_2","doi-asserted-by":"publisher","DOI":"10.1086\/344769"},{"key":"e_1_2_18_62_2","first-page":"81","article-title":"Highly active antiretroviral therapy in a large urban clinic","volume":"131","author":"Lucas GM","year":"1999","journal-title":"risk factors for virologic failure and adverse drug reactions"},{"key":"e_1_2_18_63_2","unstructured":"WalmsleySL SaskinR RaboudJ ThompsonC.Safety and efficacy of highly active antiretroviral therapy (HAART) in a clinical cohort of HIV infected Women.The XV International AIDS Conference. 2004 [Abstract B10988]."},{"key":"e_1_2_18_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207260-00020"},{"key":"e_1_2_18_65_2","doi-asserted-by":"publisher","DOI":"10.1086\/317536"},{"key":"e_1_2_18_66_2","doi-asserted-by":"publisher","DOI":"10.1086\/341084"},{"key":"e_1_2_18_67_2","doi-asserted-by":"publisher","DOI":"10.1086\/428093"},{"key":"e_1_2_18_68_2","unstructured":"RibaudoH CliffordD GulickRet al. Relationships between efavirenz pharmacokinetics side effects drug discontinuation virologic response and race: results from ACTG A5095\/A5097s.Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 132]."},{"key":"e_1_2_18_69_2","unstructured":"HaasD RibaudoH KimRet al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG study NWCS214.Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 133]."},{"key":"e_1_2_18_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00166.x"},{"key":"e_1_2_18_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85132-3"},{"key":"e_1_2_18_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000136724.15758.ae"},{"key":"e_1_2_18_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200104130-00008"},{"key":"e_1_2_18_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200104130-00008"},{"key":"e_1_2_18_75_2","first-page":"2621","article-title":"Incidence of adipose tissue alterations in first\u2010line antiretroviral therapy","volume":"162","author":"Galli M","year":"2002","journal-title":"the LipoICoNa Study"},{"key":"e_1_2_18_76_2","first-page":"18","article-title":"Fat distribution in HIV\u2010infected women in the United States","volume":"38","author":"Mulligans K","year":"2004","journal-title":"DEXA substudy in the Women's Interagency HIV Study"},{"key":"e_1_2_18_77_2","unstructured":"RaghavanS LawM El\u2010SadrW CarrA.Ethnic differences in objective measures of lipodsytrophy (LD) The XV International AIDS Conference Bangkok 2004. Abstract no. WePeB5939."},{"key":"e_1_2_18_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422511"},{"key":"e_1_2_18_79_2","first-page":"2075","article-title":"Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection","volume":"13","author":"Phillips AN","year":"1999","journal-title":"comparison of cohort studies with randomized trials"},{"key":"e_1_2_18_80_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.661"},{"key":"e_1_2_18_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199905280-00011"},{"key":"e_1_2_18_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)22008-3"},{"key":"e_1_2_18_83_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00007"},{"volume-title":"Guidance For Industry (draft). Clinical Considerations For Accelerated and Traditional Approval of Antiretroviral Drugs Using Plasma HIV RNA Measurements","year":"1999","author":"Food and Drug Administration.","key":"e_1_2_18_84_2"},{"key":"e_1_2_18_85_2","first-page":"57","article-title":"HIV\u20101 RNA response to antiretroviral treatment in 1280 participants in the Delta trial","volume":"13","author":"Delta Coordinating Committee and Virology Group.","year":"1999","journal-title":"an extended virology study"},{"key":"e_1_2_18_86_2","first-page":"291","article-title":"AIDS across Europe, 1994\u201398","volume":"356","author":"Mocroft A","year":"2000","journal-title":"the EuroSIDA tudy"},{"key":"e_1_2_18_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"e_1_2_18_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04954-X"},{"key":"e_1_2_18_89_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(99)03287-0","article-title":"Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly active antiretroviral therapy in HIV infection","volume":"353","author":"Weverling GJ","journal-title":"Lancet"},{"key":"e_1_2_18_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101183440302"},{"key":"e_1_2_18_91_2","doi-asserted-by":"publisher","DOI":"10.1086\/341466"},{"key":"e_1_2_18_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16589-6"},{"key":"e_1_2_18_93_2","first-page":"605","article-title":"Surrogate end points in clinical trials","volume":"125","author":"Fleming TR","year":"1996","journal-title":"are we being misled?"},{"key":"e_1_2_18_94_2","first-page":"237","article-title":"Perspective: validating surrogate markers","volume":"175","author":"De Gruttola V","year":"1997","journal-title":"are we being naive?"},{"key":"e_1_2_18_95_2","first-page":"319","article-title":"Risk of AIDS and death at given HIV\u2010RNA and CD4 cell count levels, according to specific antiretroviral drugs in the regimen","volume":"19","author":"Holkmann Olsen C","year":"2005","journal-title":"AIDS"},{"key":"e_1_2_18_96_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.777"},{"key":"e_1_2_18_97_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200402200-00001"},{"key":"e_1_2_18_98_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements \u2013 Clinical Considerations for Accelerated and Traditional Approval.http:\/\/www.fda.gov\/cder\/guidance\/index.htmOctober 2002."},{"key":"e_1_2_18_99_2","first-page":"165","article-title":"Non\u2010inferiority trials","volume":"22","author":"D'Agostino RB.","year":"2003","journal-title":"advances in concepts and methodology"},{"key":"e_1_2_18_100_2","first-page":"619","article-title":"Trial and error","volume":"17","author":"Phillips AN.","year":"2003","journal-title":"cross-trial comparisons of antiretroviral regimens"},{"key":"e_1_2_18_101_2","unstructured":"Committee on Safety of Medicines.http:\/\/www.mca.gov.uk\/aboutagency\/regframework\/csm\/csmhome.htm(accessed on 20 May 2005)."},{"key":"e_1_2_18_102_2","first-page":"2868","article-title":"Interventions to enhance patient adherence to medication prescriptions","volume":"288","author":"McDonald HP","year":"2002","journal-title":"scientific review"},{"key":"e_1_2_18_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00215.x"},{"key":"e_1_2_18_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00008"},{"key":"e_1_2_18_105_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200207010-00003"},{"key":"e_1_2_18_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109070-00014"},{"key":"e_1_2_18_107_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00011"},{"key":"e_1_2_18_108_2","unstructured":"BangsbergDR GuzmanD RileyED.Non nucleoside reverse transcriptase inhibitor (NNRTI) resistance occurs at lower levels of adherence then protease inhibitor (PI) resistance.15th International AIDS Conference. Bangkok July 2004 [Abstract WePeB5820]."},{"key":"e_1_2_18_109_2","doi-asserted-by":"publisher","DOI":"10.1086\/383572"},{"key":"e_1_2_18_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh162"},{"key":"e_1_2_18_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"},{"key":"e_1_2_18_112_2","unstructured":"GallantJE RodriguezAE WeinbergWet al. Early non\u2010response to tenofovir DF (TDF)+abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV)+ABC and 3TC: ESS30009 unplanned interim analysis.Program and Abstracts of the 43rd Annual ICAAC. Chicago IL 14\u201317 September 2003 [Abstract H\u20101722a]."},{"key":"e_1_2_18_113_2","unstructured":"PodzamczerD FerrerE GatellJMet al. Early virologic failure and occurrence of resistance in naive patients receiving tenofovir didanosine and efavirenz.XIII International HIV Drug Resistance Workshop. Tenerife Canary Islands 8\u201312 June 2004 [Abstract 156]."},{"key":"e_1_2_18_114_2","unstructured":"MaitlandD MoyleG HandJet al. Early virological failure in persons with viral loads >100\u2003000\u2003cps\/mL and CD4 counts <200\/\u03bcL receiving didanosine (ddI)\/tenofovir (TDF)\/efavirenz (EFV): 12 week results from a randomised comparative trial.7th International Congress on Drug Therapy in HIV infection. Glasgow 14\u201318 November 2004 [Abstract PL2.5]."},{"key":"e_1_2_18_115_2","first-page":"184","article-title":"Electronic pill\u2010boxes in the evaluation of antihypertensive treatment compliance","volume":"13","author":"Andrejak M","year":"2000","journal-title":"comparison of once daily versus twice daily regimen"},{"key":"e_1_2_18_116_2","first-page":"95","article-title":"A study of efficacy, tolerance and compliance of once\u2010daily versus twice\u2010daily metoprolol (Betaloc) in hypertension","volume":"7","author":"Baird MG","year":"1984","journal-title":"Betaloc Compliance Canadian Cooperative Study Group"},{"key":"e_1_2_18_117_2","first-page":"191","article-title":"Impact of a patient education program on adherence to HIV medication","volume":"34","author":"Goujard C","year":"2003","journal-title":"a randomized clinical trial"},{"key":"e_1_2_18_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-3991(02)00127-1"},{"key":"e_1_2_18_119_2","unstructured":"MannheimerS MorseE MattsJ.Sustained Benefit from a Long\u2010term Antiretroviral (AR) Adherence Intervention: Results of a Large Randomized Clinical Trial.15th International AIDS Conference. Bangkok July 2004 [Abstract LbOrB15]."},{"key":"e_1_2_18_120_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200310010-00007"},{"key":"e_1_2_18_121_2","first-page":"52","article-title":"Using motivational interviewing to promote adherence to antiretroviral medications","volume":"14","author":"DiIorio C","year":"2003","journal-title":"a pilot study"},{"key":"e_1_2_18_122_2","first-page":"121","article-title":"Efficacy of an educational and counselling intervention on adherence to highly active antiretroviral therapy","volume":"4","author":"Pradier C","year":"2003","journal-title":"French prospective controlled study"},{"key":"e_1_2_18_123_2","unstructured":"WagnerG KanouseD MillerLet al. Cognitive\u2010behavioural Intervention to Enhance Adherence to ART: A Randomized Clinical Trial (CCTG 578).12th Conference on Retroviruses and Opportunistic Infections. Boston MA 2005 [Abstract 614]."},{"key":"e_1_2_18_124_2","doi-asserted-by":"publisher","DOI":"10.1080\/0954012031000134700"},{"key":"e_1_2_18_125_2","first-page":"85","article-title":"Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy","volume":"9","author":"Weber R","year":"2004","journal-title":"prospective randomized trial"},{"key":"e_1_2_18_126_2","unstructured":"FischlM RodriguezA ScerpellaE.Impact of directly observed therapy on outcomes in HIV clinical trials.7th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 2000 [Abstract 71]."},{"issue":"5","key":"e_1_2_18_127_2","first-page":"S409","article-title":"Directly administered antiretroviral therapy in an urban methadone maintenance clinic","volume":"38","author":"Lucas GM","year":"2004","journal-title":"a nonrandomized comparative study"},{"key":"e_1_2_18_128_2","doi-asserted-by":"publisher","DOI":"10.1086\/421406"},{"key":"e_1_2_18_129_2","unstructured":"WitekJ RockstrohJ DonatacciL.Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy.15th International AIDS Conference. Bangkok July 2004 [Abstract WePeB5822]."},{"key":"e_1_2_18_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/387183a0"},{"key":"e_1_2_18_131_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508173330702"},{"key":"e_1_2_18_132_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8356453"},{"key":"e_1_2_18_133_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402101"},{"key":"e_1_2_18_134_2","doi-asserted-by":"publisher","DOI":"10.1086\/314628"},{"key":"e_1_2_18_135_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.7.4650-4655.1994"},{"key":"e_1_2_18_136_2","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1128\/jvi.68.9.6103-6110.1994","article-title":"Virus\u2010specific CD8+cytotoxic T\u2010lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection","volume":"68","author":"Borrow P","year":"1994","journal-title":"J Virol"},{"key":"e_1_2_18_137_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5342.1447"},{"key":"e_1_2_18_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"e_1_2_18_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-5355-7_17"},{"key":"e_1_2_18_140_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005260-00007"},{"key":"e_1_2_18_141_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402114"},{"key":"e_1_2_18_142_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010036"},{"key":"e_1_2_18_143_2","doi-asserted-by":"publisher","DOI":"10.1086\/313851"},{"key":"e_1_2_18_144_2","unstructured":"RizzardiGP CapiluppiB TambussiGet al. Effect of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV\u20101 infection.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract 759]."},{"key":"e_1_2_18_145_2","unstructured":"KhonkarlyM TambussiG CiuffredaDet al. Long term benefit of Cyclosporin A coupled with highly active antiretroviral therapy in primary HIV\u20101 infection.12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201315 February 2005 [Abstract 567]."},{"key":"e_1_2_18_146_2","unstructured":"MillerJ FinlaysonR SmithDet al. The occurrence of lipodystrophic phenomena in patients with primary HIV infection (HIV) treated with antiretroviral therapy (ARV).VII European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon Portugal 23\u201327 October 1999 [Abstract 519]."},{"key":"e_1_2_18_147_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00024"},{"key":"e_1_2_18_148_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00010"},{"key":"e_1_2_18_149_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7057.608"},{"key":"e_1_2_18_150_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00012"},{"key":"e_1_2_18_151_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200401020-00006"},{"key":"e_1_2_18_152_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111230-00006"},{"key":"e_1_2_18_153_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00009"},{"key":"e_1_2_18_154_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.20.2568"},{"key":"e_1_2_18_155_2","unstructured":"WoodR TeamTS.Sustained efficacy of nevirapine (NVP) in combination with two nucleosides in advanced treatment\u2010naive HIV infected patients with high viral loads: a B1090 substudy.XIII International AIDS Conference. Durban South Africa 28 June\u20133 July 2000 [Abstract WeOrB604]."},{"key":"e_1_2_18_156_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_18_157_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207050-00009"},{"key":"e_1_2_18_158_2","first-page":"1046","article-title":"Mortality in HIV\u2010seropositive versus \u2010seronegative persons in the era of highly active antiretroviral therapy","volume":"190","author":"Wang C","year":"2004","journal-title":"implications for when to initiate therapy"},{"key":"e_1_2_18_159_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-8-200304150-00007"},{"key":"e_1_2_18_160_2","first-page":"812","article-title":"Initiation of highly active antiretroviral therapy at CD4+T lymphocyte counts of >350\u2003cells\/\u03bcL","volume":"36","author":"Sterling TR","year":"2003","journal-title":"disease progression, treatment durability, and drug toxicity"},{"key":"e_1_2_18_161_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00004"},{"key":"e_1_2_18_162_2","first-page":"119","article-title":"Prognosis of HIV\u20101\u2010infected patients starting highly active antiretroviral therapy","volume":"360","author":"Egger M","year":"2002","journal-title":"a collaborative analysis of prospective studies"},{"key":"e_1_2_18_163_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2730"},{"key":"e_1_2_18_164_2","first-page":"673","article-title":"Systemic non\u2010Hodgkin lymphoma (NHL) in individuals with known dates of HIV seroconversion","volume":"18","author":"Bhaskaran K","year":"2004","journal-title":"incidence and predictors"},{"key":"e_1_2_18_165_2","unstructured":"ReevesI FisherM HillT SabinC on behalf of the UK Collaborative HIV Cohort (CHIC) Steering Committee.CD4 counts and the risk of lymphoma in individuals with HIV in the UK.11th Annual Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). Dublin 2005 [Abstract O47]."},{"key":"e_1_2_18_166_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200212060-00011"},{"key":"e_1_2_18_167_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00003"},{"key":"e_1_2_18_168_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300409"},{"key":"e_1_2_18_169_2","doi-asserted-by":"publisher","DOI":"10.1086\/317644"},{"key":"e_1_2_18_170_2","first-page":"283","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus\u2010 and hepatitis C virus\u2010coinfected patients","volume":"34","author":"Benhamou Y","year":"2001","journal-title":"impact of protease inhibitor therapy"},{"key":"e_1_2_18_171_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_18_172_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161010-00003"},{"key":"e_1_2_18_173_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_18_174_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000162334.12815.5b"},{"key":"e_1_2_18_175_2","unstructured":"MoyleGJ BaldwinC DentNet al. Management of protease inhibitor (PI)\u2010associated lipodystrophy by substitution with efavirenz in virologically controlled HIV\u2010infected persons.XXXIV Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA 26\u201329 September 1999 [Abstract 2064]."},{"key":"e_1_2_18_176_2","unstructured":"GoldenbergD BolyeB. Psychiatric safety of efavirenz.13th International AIDS Conference. Durban 2000 [Abstract WePeB4238]."},{"key":"e_1_2_18_177_2","unstructured":"ShafranS LefebvreE BarilJet al. Retrospective analysis of factors associated with discontinuation of EFV due to adverse effects.1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires 2001 [Abstract 537]."},{"key":"e_1_2_18_178_2","unstructured":"KasparR.Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine\u2010associated rash.XXXVIII Interscience Conference in Antimicrobial Agents and Chemotherapy. San Diego CA 24\u201327 September 1998 [Abstract I\u201064]."},{"key":"e_1_2_18_179_2","unstructured":"Important change in SUSTIVA (efavirenz) package insert \u2013 change from pregnancy category C to D. Company\u2010initiated warning letter Bristol\u2010Myers Squibb Company March 2005."},{"key":"e_1_2_18_180_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00012"},{"key":"e_1_2_18_181_2","unstructured":"MontanerJ GiglottiM CahnPet al. The effects of a short course of prednisone on the incidence of rash associated with nevirapine (Viramune).XIII World AIDS Conference. Durban South Africa 24 June\u20133 July 2000 [Abstract WePeB1378]."},{"key":"e_1_2_18_182_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"key":"e_1_2_18_183_2","doi-asserted-by":"publisher","DOI":"10.1086\/315317"},{"key":"e_1_2_18_184_2","first-page":"2603","article-title":"Dose ranging, randomized, clinical tral of atazanavir with lamivudine and stavudine in antiretroiviral naive subjects","volume":"17","author":"Murphy RL","year":"2003","journal-title":"48 week results"},{"key":"e_1_2_18_185_2","first-page":"634","article-title":"Randomized trial to evaluate indinavir\/ritonavir versus saquinavir\/ritonavir in human immunodeficiency type\u20101 infected patients","volume":"188","author":"Dragsted U","year":"2003","journal-title":"the MaxCMin1 trial"},{"key":"e_1_2_18_186_2","unstructured":"YouleM GerstoftJ FoxZet al. The final week 48 analysis of a phase IV randomized open label multicentre trial to evaluate safety and efficacy of lopinavir\/ritonavir (400\/100\u2003mg bid) versus saquinavir\/ritonavir (1000\/100\u2003mg bid): the MaxCMin2 trial.9th European AIDS Conference. Warsaw 2003 [Abstract F 11\/3]."},{"key":"e_1_2_18_187_2","first-page":"18","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424\u2010067)","volume":"32","author":"Sanne I","journal-title":"a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination wityh didanosine and stavudine in antiretrovial naive subjects"},{"key":"e_1_2_18_188_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00003"},{"key":"e_1_2_18_189_2","first-page":"1155","article-title":"Abacavir\u2010lamivudine\u2010zidovudine vs indinavir\u2010lamivudine\u2010zidovudine in antiretroviral\u2010naive HIV\u2010infected adults","volume":"285","author":"Staszewski S","year":"2001","journal-title":"a randomised equivalence trial"},{"key":"e_1_2_18_190_2","unstructured":"GulickRM RibaudoHJ ShikumaCMet al. ACTG 5095: A comparative study of 3 protease inhibitor\u2010sparing antiretroviral regimens for the initial treatment of HIV infection.2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France 13\u201316 July 2003 [Abstract Oral 41]."},{"key":"e_1_2_18_191_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030264"},{"key":"e_1_2_18_192_2","unstructured":"JemsekJ HutchersonP HarperE.Poor virological responses and early emergence of resistance in treatment naive HIV\u2010infected patients receiving a once daily triple nucleoside regimen of didanosine lamivudine and tenofovir DF.11th Conference on Retroviruses and Opportunistic Infections San Francisco 2004 [# 51]."},{"key":"e_1_2_18_193_2","unstructured":"LandmanR PeytavinG DescampsDet al. Low genetic barrier to resistance is a possible cause of early virological failures in once daily regimen of abacavir lamivudine and tenofovir: the Tonus study.11th CROI. San Francisco 2004 [#52]."},{"key":"e_1_2_18_194_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412501"},{"key":"e_1_2_18_195_2","doi-asserted-by":"publisher","DOI":"10.1086\/424009"},{"key":"e_1_2_18_196_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","article-title":"A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine\/lamivudine in HIV\u2010infected naive patients (the Combine Study)","volume":"7","author":"Podzamczer D","year":"2002","journal-title":"Antivir Ther"},{"key":"e_1_2_18_197_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00137.x"},{"key":"e_1_2_18_198_2","unstructured":"GazzardB De JesusE CampoR. The combination of tenofovir DF (TDF) emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs. fixed dose zidovudine\/lamivudine (CBV) and EFV in antiretroviral naive patients: a 24 week preliminary analysis.44th ICAAC. Washington DC 2004 [Oral presentation H\u20101137c]."},{"key":"e_1_2_18_199_2","unstructured":"GatheJ PodzamczerD JohnsonMet al. Once\u2010daily vs. twice\u2010daily lopinavir\/ritonavir in antiretroviral naive patients: 48 week results.11th CROI. San Francisco 2004 [Abstract 716]."},{"key":"e_1_2_18_200_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.191"},{"key":"e_1_2_18_201_2","first-page":"417","article-title":"Abacavir once or twice daily combined with once\u2010daily lamivudine and efavirenz for the treatment of antiretroviral\u2010naive HIV\u2010infected adults","volume":"38","author":"Moyle G","year":"2005","journal-title":"results of the Ziagen once daily in antiretroviral combination study"},{"key":"e_1_2_18_202_2","unstructured":"PodzamczerD FerrerE SanchezPet al. Toxicity and efficacy of 3TC\/EFV associated with stavudine or abacavir in antiretroviral\u2010naive patients: 48 week results of a randomized open and multicentre trial (ABCDE study).11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004 [Abstract 783]."},{"key":"e_1_2_18_203_2","unstructured":"BartlettJA JohnsonJ HerreraGet al. Initial therapy with abacavir+lamivudine (ABC+3TC) combined with efavirenz (NNRTI) amprenavir\/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS).Program and Abstracts of the 15th International AIDS Conference. Bangkok Thailand 11\u201316 July 2004 [Abstract TuPeB4544]."},{"key":"e_1_2_18_204_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131332.30548.92"},{"key":"e_1_2_18_205_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307067101"},{"key":"e_1_2_18_206_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_18_207_2","first-page":"1253","article-title":"Comparison of first\u2010line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine","volume":"363","author":"Van Leth F","year":"2004","journal-title":"a randomised open-label trial, the 2NN Study"},{"key":"e_1_2_18_208_2","unstructured":"MaggioloF RipamontiD MigliorinoGet al. Virologic efficacy of three once\u2010a\u2010day HAART regimens. Planned interim analysis.International Congress on Drug Therapy HIV. 14\u201318 November 2004;7: [Abstract P10]."},{"key":"e_1_2_18_209_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.180"},{"issue":"1","key":"e_1_2_18_210_2","first-page":"S39","article-title":"Evaluation of side effect tolerability and quality of life (QOL) measures in patients after substitution of their PI\/NNRTI with lopinavir\/ritonavir (LPv\/r)","volume":"8","author":"Hayden R","year":"2003","journal-title":"Antiviral Therapy"},{"key":"e_1_2_18_211_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200304110-00008"},{"key":"e_1_2_18_212_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00005"},{"key":"e_1_2_18_213_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00004"},{"key":"e_1_2_18_214_2","unstructured":"http:\/\/www.aidsmap.com\/treatments(accessed on 25 April 2005)."},{"key":"e_1_2_18_215_2","unstructured":"MoyleG SabinC CartledgeJet al. A 48\u2010week randomized open\u2010label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analogue in persons with lipoatrophy and sustained virological suppression on HAART.12th Conference on Retroviruses and Opportunistic Infections. Boston MA 2005 [Abstract 44LB]."},{"key":"e_1_2_18_216_2","unstructured":"MilinkovicA LopezS VidalSet al. A randomised open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function metabolic parameters and subcutaneous fat in HIV\u2010infected patients receiving antiretroviral therapy containing stavudine.12th Conference on Retroviruses and Opportunistic Infections. Boston 2005 [Abstract 857]."},{"key":"e_1_2_18_217_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.11.9404-9412.1999"},{"key":"e_1_2_18_218_2","doi-asserted-by":"publisher","DOI":"10.1086\/340312"},{"key":"e_1_2_18_219_2","unstructured":"RaffiF EsnaultJL ReliquetVet al. The Maintavir Study substitution of a non\u2010nucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients with undetectable plasma HIV\u20101 rna: 18 months follow\u2010up.XXXX Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto Canada 17\u201320 September 2000 [Abstract 474]."},{"key":"e_1_2_18_220_2","unstructured":"WinstonA PozniakA SmithAet al. Dose escalation or immediate full dose when switching from efavirenz\u2010to nevirapine\u2010based HAART? IX Annual Conference of the British HIV Association. Manchester UK 24\u201326 April 2003 [Abstract 011]."},{"key":"e_1_2_18_221_2","first-page":"181","article-title":"Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission","volume":"186","author":"Cunningham CK","year":"2002","journal-title":"a substudy of pediatric AIDS clinical trials group protocol 316"},{"key":"e_1_2_18_222_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00001"},{"key":"e_1_2_18_223_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.10.1220"},{"key":"e_1_2_18_224_2","unstructured":"DybulM ChunTW YoderCet al. Short\u2010cycle intermittent HAART a pilot study.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract 354]."},{"key":"e_1_2_18_225_2","unstructured":"FauciAS.Host factors in the pathogenesis of HIV disease: implication for therapeutic strategies.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract S16]."},{"key":"e_1_2_18_226_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301240-00009"},{"key":"e_1_2_18_227_2","doi-asserted-by":"publisher","DOI":"10.1086\/427695"},{"key":"e_1_2_18_228_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00010"},{"key":"e_1_2_18_229_2","unstructured":"GreubG CozziLepri A LedergerberBet al. Lower level HIV viral rebound and blips in patients receiving potent antiretroviral therapy.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract 522]."},{"issue":"3","key":"e_1_2_18_230_2","first-page":"89","article-title":"Prevalence and predictive value of interment viraemia in patients with viral suppression","volume":"5","author":"Havlir D","year":"2000","journal-title":"Antiviral Ther"},{"key":"e_1_2_18_231_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.7.817"},{"key":"e_1_2_18_232_2","doi-asserted-by":"publisher","DOI":"10.1086\/315334"},{"key":"e_1_2_18_233_2","unstructured":"PozniakA PlattnebergA RozenbaumW.A 48 week final analysis from a phase III double\u2010blind placebo controlled study in antiviral experienced patients (study 907).XIV International AIDS Conference. Barcelona Spain 7\u201312 July 2002 [Abstract WeOrB1266]."},{"key":"e_1_2_18_234_2","unstructured":"RouseE GerondelisP PaulsenDet al. Clonal analysis of week 12 virologic non\u2010responders receiving tenofovir\/abacavir\/lamivudine in ESS30009.Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 720]."},{"key":"e_1_2_18_235_2","unstructured":"JohnsonJ LiJF MorrisLet al. Resistance emerges in the majority of women provided intrapartum single\u2010dose nevirapine.Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 100]."},{"key":"e_1_2_18_236_2","doi-asserted-by":"publisher","DOI":"10.1086\/339014"},{"key":"e_1_2_18_237_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.350-359.2003"},{"key":"e_1_2_18_238_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501280-00007"},{"key":"e_1_2_18_239_2","unstructured":"Preliminary 48\u2010week data from phase 111 study of 433908 an investigational HIV protease inhibitor. Vertex Pharmaceuticals Press Release 24 July 2003."},{"key":"e_1_2_18_240_2","unstructured":"Bak DragstedU GerstoftJ for the MaxCmin 2 trial groupet al. The interim analysis of a phase IV randomised !open\u2010label multi\u2010centre trial to evaluate safety and efficacy of lopinavir\/ritonavir (400\/100\u2003mg bid) versus saquinavir\/ritonavir (1000\/100\u2003mg bid) in adult HIV\u20101 infection: The MaxCmin2 Trial.6th International Congress on Drug Therapy in HIV Infection. Glasgow 2002 [Abstract LB PL14.5]."},{"key":"e_1_2_18_241_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371102"},{"key":"e_1_2_18_242_2","unstructured":"MontanerJ ChungJ GuimaraesDet al. A treatment staging proposal derived from a post\u2010hoc analysis of the 48 week results from the TORO studies.15th International AIDS Conference. Bangkok 2004 [Abstract TuPEB4483]."},{"key":"e_1_2_18_243_2","first-page":"695","article-title":"How long will the benefits of highly active antiretroviral therapy (HAART) last? Treatment exhaustion among individuals infected with HIV in the UK","volume":"330","author":"Sabin A","year":"2005","journal-title":"a multicentere cohort study"},{"key":"e_1_2_18_244_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03380-1"},{"issue":"1","key":"e_1_2_18_245_2","first-page":"S218","article-title":"CD4+cell increase to highly active antiretroviral therapy (HAART) at one year is predictive of clinical outcome despite incomplete viral suppression","volume":"8","author":"Loutfy M","year":"2003","journal-title":"Antivir Ther"},{"key":"e_1_2_18_246_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440702"},{"key":"e_1_2_18_247_2","doi-asserted-by":"publisher","DOI":"10.1086\/378355"},{"key":"e_1_2_18_248_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00009"},{"key":"e_1_2_18_249_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.3.381"},{"key":"e_1_2_18_250_2","unstructured":"Centers for Disease Control and Prevention.Guidelines for the Use of Antiretroviral Agents in HIV\u2010Infected Adults and Adolescents (The Living Document). HIV\/AIDS Treatment Information Service (ATIS) Atlanta GA.http:\/\/www.hivatis.orgApril 2001.http:\/\/www.hivatis.org"},{"key":"e_1_2_18_251_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04084-7"},{"issue":"3","key":"e_1_2_18_252_2","first-page":"71","article-title":"Phenotypic analysis of the Viradapt study","volume":"5","author":"Clevenbergh P","year":"2000","journal-title":"correlation with genotypic resistance and PI plasma levels"},{"key":"e_1_2_18_253_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199902040-00001"},{"key":"e_1_2_18_254_2","unstructured":"WorkmanC MussenR SullivanJ.Salvage therapy using six drugs in heavily pretreated patients.V Conference on Retroviruses and Opportunistic Infections. Chicago IL 31 January\u20135 February 1998 [Abstract 426]."},{"key":"e_1_2_18_255_2","unstructured":"KatlamaC DominguezS DuvivierCet al. Long\u2010term benefit of treatment interruption in salvage therapy (GIGAHAART ANRS 097).X Conference on Retroviruses and Opportunistic Infections. Boston MA 10\u201314 February 2003 [Abstract 68]."},{"key":"e_1_2_18_256_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00010"},{"key":"e_1_2_18_257_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00007"},{"key":"e_1_2_18_258_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/135965350300800207","article-title":"Changes in viral load in people with virological failure who remain on the same HAART regimen","volume":"8","author":"Cozzi\u2010Lepri A","year":"2003","journal-title":"Antivir Ther"},{"key":"e_1_2_18_259_2","unstructured":"DeeksS WrinT HohRet al. Response to salvage therapy in patients undergoing a structured treatment interruption.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract 292]."},{"key":"e_1_2_18_260_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035103"},{"key":"e_1_2_18_261_2","first-page":"217","article-title":"Benefit of treatment interruption in HIV\u2010infected patients with multiple therapeutic failures","volume":"18","author":"Katlama C","year":"2004","journal-title":"a randomized controlled trial (ANRS 097)"},{"key":"e_1_2_18_262_2","unstructured":"LawrenceJ MayersD the study CPCRA 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDSet al. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi\u2010drug resistant HIV.X Conference on Retroviruses and Opportunistic Infections. Boston MA 10\u201314 February 2003 [Abstract 67]."},{"key":"e_1_2_18_263_2","first-page":"481","article-title":"An open\u2010label randomized clinical trail of novel therapeutic strategies for HIV\u2010infected patients in whom atniretorivral therapy has fialed","volume":"24","author":"Kyriakides TC","year":"2003","journal-title":"rationale and design of the OPTIMA trial"},{"key":"e_1_2_18_264_2","unstructured":"LeithJ WalmsleyS KatlamaCet al. Pharmacokinetics and safety of tipranavir\/ritonavir (TPV\/r) alone or in combination with saquinavir (SQV) amprenavir (APV) or lopinavir (LPV): interim analysis of BI1182.51.Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome Italy 1\u20133 April 2004 [Abstract 5.1]."},{"key":"e_1_2_18_265_2","unstructured":"KatlamaC ArastehK ClotetBet al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings.2nd IAS Conference on HIV Pathogenesis and Treatment. Paris 2003 [Abstract LB2]."},{"key":"e_1_2_18_266_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","article-title":"Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe","volume":"9","author":"Pillay D.","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_18_267_2","doi-asserted-by":"publisher","DOI":"10.1086\/420789"},{"key":"e_1_2_18_268_2","unstructured":"BennetD McCormickL KlineRet al. U.S. Surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera.Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 674]."},{"key":"e_1_2_18_269_2","first-page":"440","article-title":"Use of genotypic resistance testing to guide HIV therapy","volume":"134","author":"Weinstein MC","year":"2001","journal-title":"clinical impact and cost-effectiveness"},{"key":"e_1_2_18_270_2","unstructured":"SaxPE IslamR LosinaEet al. Should resistance testing be done in antiretroviral\u2010naive patients? A cost\u2010effectiveness analysis.XIV International AIDS Conference. Barcelona Spain 7\u201312 July 2002 [Abstract MoPeB3129]."},{"key":"e_1_2_18_271_2","doi-asserted-by":"publisher","DOI":"10.1086\/427192"},{"key":"e_1_2_18_272_2","first-page":"2195","article-title":"Drug\u2010resistance genotyping in HIV\u20101 therapy","volume":"353","author":"Durant J","year":"1999","journal-title":"the VIRADAPT randomised controlled trial"},{"key":"e_1_2_18_273_2","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy","volume":"14","author":"Baxter JD","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_18_274_2","first-page":"209","article-title":"Clinical utility of HIV\u20101 genotyping and expert advice","volume":"16","author":"Tural C","year":"2002","journal-title":"the Havana trial"},{"key":"e_1_2_18_275_2","first-page":"369","article-title":"Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy","volume":"16","author":"Cingolani A","year":"2002","journal-title":"a randomised study (ARGENTA)"},{"key":"e_1_2_18_276_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00009"},{"key":"e_1_2_18_277_2","first-page":"295","article-title":"A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy","volume":"19","author":"Haubrich RH","year":"2005","journal-title":"CCTG 575"},{"key":"e_1_2_18_278_2","first-page":"727","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure","volume":"16","author":"Meynard JL","year":"2002","journal-title":"a randomised trial"},{"key":"e_1_2_18_279_2","unstructured":"BlancoJL ValdecillosG ArroyoJRet al. A prospective randomised study on the usefulness of genotypic resistance tests versus real phenotypic resistance tests in heavily pre\u2010treated patients with virological failure (VIHRES study).XIV International AIDS Conference. Barcelona Spain 7\u201312 July 2002 [Abstract TuPeB4624]."},{"key":"e_1_2_18_280_2","first-page":"723","article-title":"Long\u2010term efficacy of routine access to antiretroviral\u2010resistance testing in HIV type 1\u2010infected patients","volume":"38","author":"Wegner SA","year":"2004","journal-title":"results of the clinical efficacy of resistance testing trial"},{"key":"e_1_2_18_281_2","first-page":"268","article-title":"Real versus virtual phenotype to guide treatment in heavily pretreated patients","volume":"32","author":"Mazzotta F","year":"2003","journal-title":"48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial"},{"key":"e_1_2_18_282_2","first-page":"577","article-title":"Phenotype or virtual phenotype for choosing antiretroviral therapy after failure","volume":"8","author":"Perez\u2010Elias MJ","year":"2003","journal-title":"a prospective, randomized study"},{"key":"e_1_2_18_283_2","first-page":"1","article-title":"Antiretroviral drug resistance testing in patients with HIV\u20101 infection","volume":"3","author":"Torre D","year":"2002","journal-title":"a meta-analysis study"},{"key":"e_1_2_18_284_2","unstructured":"LovedayC DunnDT GreenH RinehartA McKennaP on behalf of the ERA steering committee.XII international HIV Drug Resistance Workshop. Cabo del Sol Mexico 10\u201314 June 2003.http:\/\/www.ctu.mrc.ac.uk\/penta\/trials\/htm"},{"key":"e_1_2_18_285_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912240-00001"},{"key":"e_1_2_18_286_2","first-page":"119","article-title":"International AIDS Society\u2010USA Drug Resistance Mutations Group. Update of the drug resistance mutations in HIV\u20101: 2004","volume":"12","year":"2004","journal-title":"Top HIV Med"},{"key":"e_1_2_18_287_2","doi-asserted-by":"publisher","DOI":"10.1086\/324510"},{"key":"e_1_2_18_288_2","first-page":"F33","article-title":"The clinical relevance of non\u2010nucleoside reverse transcriptase inhibitor hypersusceptibility","volume":"16","author":"Haubrich RH","year":"2002","journal-title":"a prospective cohort analysis"},{"key":"e_1_2_18_289_2","first-page":"F41","article-title":"Hypersusceptibility to non\u2010nucleoside reverse transcriptase inhibitors in HIV\u20101","volume":"16","author":"Whitcomb JM","year":"2002","journal-title":"clinical, phenotypic and genotypic correlates"},{"key":"e_1_2_18_290_2","first-page":"1688","article-title":"Mutations in HIV\u20101 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse\u2010transcriptase inhibitors","volume":"189","author":"Tozzi V","year":"2004","journal-title":"effect on response to efavirenz-based therapy in an urban observational cohort"},{"key":"e_1_2_18_291_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00001"},{"key":"e_1_2_18_292_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200100005-00021"},{"key":"e_1_2_18_293_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg198"},{"key":"e_1_2_18_294_2","unstructured":"GarraffoR LavrutT PierreB Durantet al. Efavirenz and nevirapine concentration\u2010effect retlationships in HIV\u2010infected patients pharmacologically followed by routine therapetuc drug monitoring (TDM).IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes France 27\u201329 March 2003 [Abstract 26]."},{"key":"e_1_2_18_295_2","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects","volume":"18","author":"Haas DW","year":"2004","journal-title":"an Adult AIDS Clinical Trials Group study"},{"key":"e_1_2_18_296_2","unstructured":"La PorteC Van Der EndeM GyssensIet al. Gender differences in nevirapine and efavirenz pharmacokinetics.4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes 27\u201329 March 2003 [Abstracts 10: P 3.1 and 15: P 3.6]."},{"issue":"1","key":"e_1_2_18_297_2","first-page":"S5","article-title":"Therapeutic drug monitoring in HIV infection","volume":"16","author":"Back D","year":"2002","journal-title":"current status and future directions"},{"key":"e_1_2_18_298_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00003"},{"key":"e_1_2_18_299_2","unstructured":"VeldkampAI Van HeeswijkRPG MathotRAAet al. Evaluation of exposure\u2010response relationships for the non\u2010nucloeside reverse transcriptase inhibitor (NNRTI) nevirapine in a cohort of HIV\u2010infected individuals.II International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk The Netherlands 2\u20134 April 2001 [Abstract 5.4]."},{"key":"e_1_2_18_300_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_18_301_2","unstructured":"Van LethF KappelhoffB the 2NN Study groupet al. Minimum Plasma Concentrations of Nevirapine and Efavirenz in Relation to Virologic Failure in Antiretroviral\u2010naive Patients.12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 80]."},{"key":"e_1_2_18_302_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002030-199903110-00005","article-title":"Urological complaints in relation to indinavir plasma concentrations in HIV\u2010infected patients","volume":"13","author":"Dieleman JP","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_18_303_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.701-705.2001"},{"key":"e_1_2_18_304_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.d01-3339.x"},{"key":"e_1_2_18_305_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001070-00007"},{"key":"e_1_2_18_306_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00020"},{"key":"e_1_2_18_307_2","unstructured":"BoffitoM BonoraS SiniccoA RaiteriRet al. Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir\/ritonavir\u2010containing regimens.IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes France 27\u201329 March 2003 [Abstract P4.4]."},{"key":"e_1_2_18_308_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01452.x"},{"key":"e_1_2_18_309_2","unstructured":"Gonzalez de RequenaD BonoraS CantaFet al. Atazanavir Ctrough Is Associated with Efficacy and Safety: Definition of Therapeutic Range.12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325 February 2005 [Abstract 645]."},{"key":"e_1_2_18_310_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.4009-4012.2002"},{"key":"e_1_2_18_311_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/135965350400900105","article-title":"Changes in body fat composition after 1 year of salvage therapy with lopinavir\/ritonavir\u2010containing regimens and its relationship with lopinavir plasma concentrations","volume":"9","author":"Gutierrez F","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_18_312_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00006"},{"key":"e_1_2_18_313_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00007"},{"key":"e_1_2_18_314_2","first-page":"2311","article-title":"PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors","volume":"22","author":"Clevenbergh P","year":"2002","journal-title":"12 week results"},{"key":"e_1_2_18_315_2","first-page":"352","article-title":"GENOPHAR","volume":"5","author":"Bossi P","year":"2004","journal-title":"a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy"},{"key":"e_1_2_18_316_2","unstructured":"Mentr\u00e9F DuvalX ReyEet al. Prospective trial to evaluate how therapeutic drug monitoring of protease inhibitors increases virologic success and tolerance of HAART (COPHAR 2 \u2010 ANRS 111 trial).12th CROI. Boston 2005 [Abstract 639]."},{"key":"e_1_2_18_317_2","unstructured":"NettlesR Kieffer1T Parsons1Tet al. Frequent sampling in virologically suppressed patients taking HIV protease inhibitors or non\u2010nucleoside reverse transcriptase inhibitors defines intra\u2010individual pharmacokinetic variability.12th CROI. 2005 [Abstract 642]."},{"key":"e_1_2_18_318_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922204322996509"},{"key":"e_1_2_18_319_2","unstructured":"CastagnaA DaniseA HassonHet al. The normalized inhibitory quotient (NIQ) of Lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV\u20101\u2010infected individuals.9th Conference on Retroviruses and Opportunistic Infections. Seattle WA 24\u201328 February 2002 [Abstract 128]."},{"key":"e_1_2_18_320_2","unstructured":"BertzR LiJ KingMet al. Lopinavir inhibitory quotient predicts virologic response in highly antiretroviral\u2010experienced patients receiving high\u2010dose lopinavir\/ritonavir.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 134]."},{"key":"e_1_2_18_321_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.594-600.2003"},{"key":"e_1_2_18_322_2","unstructured":"MarcelinAG DelaugerreC KtorzaNet al. Genotypic and phenotypic inhibitory quotients as predictors of the virological response to ritonavir\/amprenavir containing regimen in HIV\u20101 protease inhibitor experienced patients.Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow UK 14\u201318 November 2004 [Plenary Session 6.5]."},{"key":"e_1_2_18_323_2","unstructured":"XuF TomkinsS YatesPet al. Genotypic inhibitory quotient predicts response to fosamprenavir\/ritonavir.Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow UK 14\u201318 November 2004 [P143]."},{"key":"e_1_2_18_324_2","first-page":"359","article-title":"Deep salvage with amprenavir and lopinavir\/ritonavir","volume":"35","author":"De Luca A","year":"2004","journal-title":"correlation of pharmacokinetics and drug resistance with pharmacodynamics"},{"key":"e_1_2_18_325_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200209270-00016"},{"key":"e_1_2_18_326_2","first-page":"262","article-title":"Individualizing salvage regimens","volume":"17","author":"Casado JL","year":"2003","journal-title":"the inhibitory quotient (Ctrough\/IC50) as predictor of virological response"},{"key":"e_1_2_18_327_2","doi-asserted-by":"publisher","DOI":"10.1086\/382754"},{"key":"e_1_2_18_328_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3907-3916.2002"},{"key":"e_1_2_18_329_2","unstructured":"ValdezH McCallisterS HallDB KohlbrennerVM MayersDL.Most highly treatment experienced tipranavir\/ritonavir recipients achieve inhibitory quotients associated with large week 24 viral load reductions.Frontiers in Drug Development for Antiretroviral Therapies meeting Montego Bay Jamaica 12\u201316 December 2004 [Abstract 039]."},{"key":"e_1_2_18_330_2","unstructured":"BMS warning. REYATAZ\u00ae(atazanavir sulfate) with or without Norvir\u00ae(ritonavir) and proton pump inhibitors should not be coadministered: important new pharmacokinetic data. Dear Doctor letter. December 2004."},{"key":"e_1_2_18_331_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.467-469.2005"},{"key":"e_1_2_18_332_2","unstructured":"RubleinJC DonovanBJ HollowellSBet al. Effect of omeprazole on the plasma concentrations of indinavir in HIV\u2010negative subjects. Single dose 800\u2003mg IDV. Cmin and AUC were similar to historical control when IDV administered with 200\u2003mg RTV.43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL USA 14\u201317 September 2003 [Abstract A\u20101611]."},{"key":"e_1_2_18_333_2","unstructured":"Van HeeswijkR SaboJP CooperCet al. The pharmacokinetic interaction between Tipranavir\/Ritonavir (500\/200) bid and atorvastatin antacid and CYP3A4 in healthy adult volunteers.5nd International Workshop on Clinical Pharmacology of HIV Therapy. Rome Italy 1\u20133 April 2004 [Abstract 5.2]."},{"key":"e_1_2_18_334_2","unstructured":"TaylorS AllenS FidlerSet al. Stop Study: After discontinuation of efavirenz plasma concentrations may persist for 2 weeks or longer.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 8\u201311 February 2004 [Abstract 131]."},{"key":"e_1_2_18_335_2","unstructured":"ManosuthiW SungkanuparphS VibhagoolAet al. A randomized controlled trial of efavirenz 600\u2003mg\/day versus 80\u2003mg\/day in HIV\u2010infected patients with tuberculosis to study plasma efavirenx level virological and immunological outcomes. A preliminary result.XV World AIDS Conference. Bangkok 2004 [MoOrB1013]."},{"key":"e_1_2_18_336_2","unstructured":"FriedlandG JackC KhooS LallooU NaidooV.Efavirenz levels and clinical outcomes in patients with TB and HIV treated concomitantly with ART and rifampin\u2010containing TB regimen.12th CROI. Boston MA 2005 [Abstract 891]."},{"key":"e_1_2_18_337_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.643-649.2005"},{"key":"e_1_2_18_338_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.821-826.2000"},{"key":"e_1_2_18_339_2","doi-asserted-by":"publisher","DOI":"10.1086\/426021"},{"key":"e_1_2_18_340_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00030"},{"key":"e_1_2_18_341_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00002"},{"key":"e_1_2_18_342_2","doi-asserted-by":"publisher","DOI":"10.1086\/376835"},{"key":"e_1_2_18_343_2","doi-asserted-by":"crossref","unstructured":"LiechtyC AlexanderC HarriganRet al. Are random antiretroviral drug levels associated with objectively measured adherence behaviour?10th Conference on Retroviruses and Opportunistic Infections. Boston MA 10\u201314 February 2003 [Abstract 529].","DOI":"10.2165\/00128413-200313780-00026"},{"key":"e_1_2_18_344_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_18_345_2","first-page":"1046","article-title":"HIV nucleoside analogues","volume":"354","author":"Morris AA","year":"1999","journal-title":"new adverse effects on mitochondria?"},{"key":"e_1_2_18_346_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_18_347_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199903110-00004"},{"issue":"5","key":"e_1_2_18_348_2","first-page":"9","article-title":"Changes in HIV\u2010associated fat maldistribution over time","volume":"5","author":"Lichtenstein KA","year":"2000","journal-title":"Antivir Ther"},{"key":"e_1_2_18_349_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06102-4"},{"key":"e_1_2_18_350_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199911120-00019"},{"key":"e_1_2_18_351_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03391-1"},{"key":"e_1_2_18_352_2","first-page":"57","article-title":"Lipodystrophy syndrome in HIV infection","volume":"23","author":"Behrens GM","year":"2000","journal-title":"what is it, what causes it and how can it be managed?"},{"key":"e_1_2_18_353_2","first-page":"413","article-title":"Mitochondrial toxicity hypothesis for lipoatrophy","volume":"15","author":"Moyle G.","year":"2001","journal-title":"a refutation"},{"key":"e_1_2_18_354_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904160-00020"},{"key":"e_1_2_18_355_2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long\u2010term nucleoside analogue therapy","volume":"13","author":"Saint\u2010Marc T","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_18_356_2","unstructured":"TashimaK StrykerR SkeistDet al. Lack of clinical lipodystrophy in patients receiving efavirenz+NRTI in study 006.XXXIX Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA 26\u201329 September 1999 [Abstract 1304]."},{"key":"e_1_2_18_357_2","unstructured":"Van Der ValkM GisolfE ReissPet al. Increased risk of lipodystrophy when including NRTIs in the treatment of HIV\u20101 infection with PIs: results from a randomised controlled trial.2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto Canada September 2000 [Abstract P78]."},{"key":"e_1_2_18_358_2","unstructured":"CohenC CameronW XuYet al. Effects of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV\u2010infected cohort.2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto 13\u201315 September 2000 [Abstract P56]."},{"key":"e_1_2_18_359_2","first-page":"116","article-title":"HIV\u2010associated lipodystrophy","volume":"2","author":"Mallon PW","year":"2002","journal-title":"description, pathogenesis, and molecular pathways"},{"key":"e_1_2_18_360_2","first-page":"L18","article-title":"Prospective study of regional body composition in antiretroviral\u2010naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384","author":"Dube M","year":"2002","journal-title":"Antivir Ther"},{"key":"e_1_2_18_361_2","first-page":"263","article-title":"Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine","volume":"38","author":"Cherry CL","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_18_362_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00002"},{"key":"e_1_2_18_363_2","first-page":"263","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus\u2010infected patients switched from stavudine to abacavir or zidovudine","volume":"38","author":"McComsey GA","year":"2004","journal-title":"the results of the TARHEEL study"},{"key":"e_1_2_18_364_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200107010-00004"},{"key":"e_1_2_18_365_2","first-page":"2489","article-title":"Thymidine analogue withdrawal for lipoatrophic patients on protease\u2010sparing therapy improves lipoatrophy but compromises antiviral control","volume":"16","author":"Smith DE","year":"2002","journal-title":"the PIILR extension study"},{"key":"e_1_2_18_366_2","first-page":"1029","article-title":"Reversibility of lipoatrophy in HIV\u2010infected patients 2 years after switching from a thymidine analogue to abacavir","volume":"18","author":"Martin A","year":"2004","journal-title":"the MITOX Extension Study"},{"key":"e_1_2_18_367_2","first-page":"801","article-title":"Effects of zidovudine, stavudine and beta\u2010aminoisobutyric acid on lipid homeostasis in mice","volume":"9","author":"Maisonneuve C","year":"2004","journal-title":"possible role in human fat wasting"},{"key":"e_1_2_18_368_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00010"},{"key":"e_1_2_18_369_2","first-page":"700","article-title":"Atherogenic dyslipidemia in HIV\u2010infected individuals treated with protease inhibitors","volume":"100","author":"Periard D","year":"1999","journal-title":"the Swiss HIV Cohort Study"},{"key":"e_1_2_18_370_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00005"},{"key":"e_1_2_18_371_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.4.918"},{"key":"e_1_2_18_372_2","first-page":"58","article-title":"Gender differences in antiretroviral drug\u2010related adipose tissue alterations","volume":"34","author":"Galli M","year":"2003","journal-title":"women are at higher risk than men and develop particular lipodystrophy patterns"},{"key":"e_1_2_18_373_2","first-page":"1559","article-title":"Regulation of adiponectin in human immunodeficiency virus\u2010infected patients","volume":"88","author":"Tong Q","year":"2003","journal-title":"relationship to body composition and metabolic indices"},{"key":"e_1_2_18_374_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"e_1_2_18_375_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000228200"},{"key":"e_1_2_18_376_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.6.1425"},{"key":"e_1_2_18_377_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00005"},{"key":"e_1_2_18_378_2","first-page":"F1","article-title":"Indinavir acutely inhibits insulin\u2010stimulated glucose disposal in humans","volume":"16","author":"Noor MA","year":"2002","journal-title":"a randomized, placebo-controlled study"},{"key":"e_1_2_18_379_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403050-00008"},{"key":"e_1_2_18_380_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm782"},{"key":"e_1_2_18_381_2","unstructured":"NoorMA GraselaD ParkerRAet al. The effect of atazanavir vs lopinavir\/ritonavir on insulin\u2010stimulated glucose disposal rate in healthy subjects. In:Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA February 8\u201311 2004 [Abstract 702]."},{"key":"e_1_2_18_382_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00143.x"},{"key":"e_1_2_18_383_2","first-page":"589","article-title":"Managing metabolic disturbances and lipodystrophy","volume":"11","author":"Moyle G","year":"2001","journal-title":"diet, exercise, and smoking advice"},{"key":"e_1_2_18_384_2","first-page":"479","article-title":"Switching from a PI\u2010based to a PI\u2010sparing regimen for management of metabolic or clinical fat redistribution","volume":"10","author":"Moyle G","year":"2000","journal-title":"AIDS Reader"},{"key":"e_1_2_18_385_2","unstructured":"Van LethF HallD LangeJMA ReissP.Increase in high\u2010density lipoprotein cholesterol when using nevirapine and\/or efavirenz is maintained up to 2 years.15th International AIDS Conference. Bangkok 2004 [Abstract WePpB2065]."},{"key":"e_1_2_18_386_2","first-page":"472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome","volume":"284","author":"Hadigan C","year":"2000","journal-title":"a randomized controlled trial"},{"key":"e_1_2_18_387_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"e_1_2_18_388_2","unstructured":"CalmyA HirschelB KarsegaardLet al. A pilot sstudy for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes.III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens Greece 23\u201326 October 2001 [Abstract 43]."},{"key":"e_1_2_18_389_2","unstructured":"VisnegarwalaF MaldonadoMR.Use of PPAR\u2010modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome.III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens Greece 23\u201326 October 2001 [Abstract 124]."},{"key":"e_1_2_18_390_2","unstructured":"Schwarzet al.The third international workshop on adverse reactions and lipodystrophy in HIV. Athens Greece October 2001 [Abstract 27]."},{"key":"e_1_2_18_391_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00007"},{"key":"e_1_2_18_392_2","unstructured":"MillerJ CarrA BrownD CooperDA.A randomised double blind study of gemfibrozil (GF) for the treatment of protease inhibitor\u2010associated hypertriglyceridaemia.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL 4\u20138 February 2001 [Abstract 540]."},{"key":"e_1_2_18_393_2","unstructured":"http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol(accessed on 26 April 2005)."},{"key":"e_1_2_18_394_2","first-page":"2471","article-title":"Polylactic acid implants (New\u2010Fill) to correct facial lipoatrophy in HIV\u2010infected patients","volume":"17","author":"Valantina M","year":"2003","journal-title":"results of the open-label study VEGA"},{"key":"e_1_2_18_395_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00190.x"},{"key":"e_1_2_18_396_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200311210-00018"},{"key":"e_1_2_18_397_2","unstructured":"MestDR HumbleG.Safety and efficacy of intradermal poly\u2010L\u2010lactic acid (Sculptra) injections in patients with HIV\u2010associated facial lipoatrophy.6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington DC 2004 [Abstract 59]."},{"key":"e_1_2_18_398_2","unstructured":"HillebrandME StrackeeSD Van UldenBGJ.Treatment of facial lipoatrophy with polylactic acid: the PLA\u2010Study.The XIV International AIDS Conference. 2002 [Abstract C10946]."},{"key":"e_1_2_18_399_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000152834.02912.98"},{"key":"e_1_2_18_400_2","unstructured":"Lafaurie DolivoM BouluDet al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV\u2010infected patients: results from a cohort of 94 patients.11th CROI. 2004 [Abstract 726]."},{"key":"e_1_2_18_401_2","unstructured":"FDA report on polylactic acid.http:\/\/aidsinfo.nih.gov\/drugs\/htmldrug_tech.asp?int_id=04032004 (accessed on 26 April 2005)."},{"key":"e_1_2_18_402_2","unstructured":"GuaraldiG OrlandoG De FazioDet al. Prospective partially randomized 24\u2010week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV\u2010related facial lipoatrophy.6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington DC 2004 [Abstract 12]."},{"key":"e_1_2_18_403_2","unstructured":"GuaraldiG OrlandoG De FazioDet al. Autologous fat transfer for the treatment of HIV\u2010related face lipoatrophy: a long follow\u2010up experience.6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington DC 2004 [Abstract 87]."},{"key":"e_1_2_18_404_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200209270-00026"},{"key":"e_1_2_18_405_2","doi-asserted-by":"publisher","DOI":"10.1080\/14764170310021922"},{"key":"e_1_2_18_406_2","unstructured":"CasavantesJC GottliebM.Bio\u2010Alcamid a high\u2010volume injectable prosthesis for facial reconstitution in HIV\u2010related lipoatrophy: report on 100 patients.6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington DC 2004 [Abstract 60]."},{"key":"e_1_2_18_407_2","unstructured":"SerraMS OyafusoLK.Soft tissue augmentation with polymethymethacylate (PMMA) for correction of lipodystrophy related body fat atrophy.6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington DC 2004 [Abstract 49]."},{"key":"e_1_2_18_408_2","unstructured":"OyafusoLKM SerraMS TroppeBM.Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow\u2010up.The XV International AIDS Conference. 2004 [Abstract MoOrB1060]."},{"key":"e_1_2_18_409_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)90004-3"},{"key":"e_1_2_18_410_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04579-7"},{"key":"e_1_2_18_411_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(99)70244-1"},{"key":"e_1_2_18_412_2","first-page":"364","article-title":"Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment","volume":"32","author":"Brivet FG","year":"2000","journal-title":"a respiratory chain dysfunction?"},{"key":"e_1_2_18_413_2","first-page":"5","article-title":"Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors","volume":"13","author":"Brinkman K","year":"2000","journal-title":"a looming obstacle for long-term antiretroviral therapy?"},{"key":"e_1_2_18_414_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80064-8"},{"key":"e_1_2_18_415_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200202010-00002"},{"key":"e_1_2_18_416_2","unstructured":"LonerganT McComseyG FisherRet al. Improvements in symptomatic hyperlactatemia are observed after 12 weeks when stavudine is replaced by either abacavir or zidovudine.III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens Greece 2001 [Abstract 81]."},{"key":"e_1_2_18_417_2","unstructured":"MallonP SedwellR RogersGet al. The efect of rosiglitaozne on PPAR\u00e3expression in human adipose tissue is limited by continued exposure to thymidine NRTI.12th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 2005 [Abstract 41]."},{"key":"e_1_2_18_418_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-1-199301010-00007"},{"key":"e_1_2_18_419_2","first-page":"1433","article-title":"Hepatomegaly and steatosis in HIV\u2010infected patients receiving nucleoside analogue antiretroviral therapy","volume":"90","author":"Fortang IS","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_18_420_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200104130-00007"},{"key":"e_1_2_18_421_2","doi-asserted-by":"publisher","DOI":"10.1086\/313912"},{"key":"e_1_2_18_422_2","first-page":"2723","article-title":"Symptomatic hyperlactataemia","volume":"14","author":"G\u00e9rard Y","year":"2000","journal-title":"an emerging complication of antiretroviral therapy"},{"key":"e_1_2_18_423_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199904000-00015"},{"key":"e_1_2_18_424_2","first-page":"192","article-title":"Lactic acidosis and hepatic steatosis associated with use of stavudine","volume":"133","author":"Miller KD","year":"2000","journal-title":"report of four cases"},{"key":"e_1_2_18_425_2","unstructured":"VrouenraetsS TreskesM RegezRMet al. The occurrence of hyperlactatemia in HIV\u2010infected patients on NRTI treatment.XIII International AIDS Conference. Durban 2000 [Abstract TuPpB1234]."},{"key":"e_1_2_18_426_2","unstructured":"MoyleGJ DattaD MandaliaSet al. Hyperlactataemia and Lactic Acidosis during antiretroviral therapy: relevance reproducibility and possible risk factors.3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens Greece 2001 [Abstract 98]."},{"key":"e_1_2_18_427_2","first-page":"61","article-title":"Clinical features and risk factors of lactic acidosis following long\u2010term antiretroviral therapy","volume":"11","author":"Ter Hofstede HJM","year":"2000","journal-title":"4 fatal cases"},{"key":"e_1_2_18_428_2","first-page":"2484","article-title":"Survival of a human immunodeficiency virus patient with nucleoside\u2010induced lactic acidosis","volume":"14","author":"Chodock R","year":"1999","journal-title":"role of haemodialysis treatment"},{"key":"e_1_2_18_429_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2346.1999.00586.x"},{"key":"e_1_2_18_430_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00523-1"},{"key":"e_1_2_18_431_2","unstructured":"BrookMG GilsonR WilkinsE the BHIVA Hepatitis Guidelines Writing Committee.BHIVA Guidelines: HIV and Chronic Hepatitis. Co\u2010Infection with HIV and Hepatitis B Virus Infection.http:\/\/www.bhiva.org."},{"key":"e_1_2_18_432_2","unstructured":"NelsonM MatthewsG BrookMG the BHIVA Hepatitis Guidelines Writing Committee.BHIVA Guidelines: HIV and Chronic Hepatitis. Co\u2010Infection with HIV and Hepatitis C Virus Infection.http:\/\/www.bhiva.org."},{"key":"e_1_2_18_433_2","unstructured":"RockstrohJ KonopnickiD SorianoVet al. Hepatitis B and Hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality AIDS progression and response to HAART.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA 2004 [Abstract 799]."},{"key":"e_1_2_18_434_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200205303462202"},{"key":"e_1_2_18_435_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200308150-00009"},{"key":"e_1_2_18_436_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11913-1"},{"key":"e_1_2_18_437_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300525"},{"key":"e_1_2_18_438_2","unstructured":"GishR LeungN WangCet al. Resistance to emtricitabine may develops less frequently than to lamivudine.53rd AASLD. Boston 2002 [Abstract 838]."},{"key":"e_1_2_18_439_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00002"},{"key":"e_1_2_18_440_2","doi-asserted-by":"publisher","DOI":"10.1086\/424012"},{"key":"e_1_2_18_441_2","doi-asserted-by":"publisher","DOI":"10.1086\/380398"},{"key":"e_1_2_18_442_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"e_1_2_18_443_2","first-page":"2839","article-title":"Pegylated interferon alfa\u20102b vs standard interferon alfa\u20102b, plus ribavirin, for chronic hepatitis C in HIV\u2010infected patients","volume":"292","author":"Carrat F","year":"2004","journal-title":"a randomized controlled trial"},{"key":"e_1_2_18_444_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032653"},{"key":"e_1_2_18_445_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03618-7"},{"key":"e_1_2_18_446_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04920-5"},{"key":"e_1_2_18_447_2","first-page":"543","article-title":"Report of three cases of hyperlactacidemia\/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients","volume":"202","author":"Montes RML","year":"2002","journal-title":"Rev Clin Esp"},{"key":"e_1_2_18_448_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.1.74"},{"key":"e_1_2_18_449_2","first-page":"767","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV\u2010infected patients with chronic hepatitis C","volume":"18","author":"Mac\u00edas J","year":"2004","journal-title":"harmful impact of nevirapine"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.0311b.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.0311b.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:10:44Z","timestamp":1696936244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.0311b.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":448,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1468-1293.2005.0311b.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.0311b.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}